Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.52
NAS:AMAG's Cash-to-Debt is ranked lower than
87% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. NAS:AMAG: 0.52 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AMAG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: No Debt Max: No Debt
Current: 0.52
0.29
No Debt
Equity-to-Asset 0.41
NAS:AMAG's Equity-to-Asset is ranked lower than
77% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NAS:AMAG: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AMAG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.82 Max: 0.99
Current: 0.41
0.33
0.99
Debt-to-Equity 0.94
NAS:AMAG's Debt-to-Equity is ranked lower than
81% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 0.26 vs. NAS:AMAG: 0.94 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:AMAG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.73  Med: 1.07 Max: 1.17
Current: 0.94
0.73
1.17
Debt-to-EBITDA -4.77
NAS:AMAG's Debt-to-EBITDA is ranked lower than
99.99% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. NAS:AMAG: -4.77 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:AMAG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.77  Med: 6.71 Max: 114.16
Current: -4.77
-4.77
114.16
Piotroski F-Score: 5
Altman Z-Score: -0.05
Beneish M-Score: -3.01
WACC vs ROIC
4.32%
-8.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -45.01
NAS:AMAG's Operating Margin % is ranked higher than
57% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. NAS:AMAG: -45.01 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AMAG' s Operating Margin % Range Over the Past 10 Years
Min: -4107.64  Med: -72.84 Max: 26.59
Current: -45.01
-4107.64
26.59
Net Margin % -35.35
NAS:AMAG's Net Margin % is ranked higher than
59% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. NAS:AMAG: -35.35 )
Ranked among companies with meaningful Net Margin % only.
NAS:AMAG' s Net Margin % Range Over the Past 10 Years
Min: -3696.96  Med: -71.06 Max: 109.19
Current: -35.35
-3696.96
109.19
ROE % -23.46
NAS:AMAG's ROE % is ranked higher than
60% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: -39.05 vs. NAS:AMAG: -23.46 )
Ranked among companies with meaningful ROE % only.
NAS:AMAG' s ROE % Range Over the Past 10 Years
Min: -52.39  Med: -15.27 Max: 42.96
Current: -23.46
-52.39
42.96
ROA % -9.09
NAS:AMAG's ROA % is ranked higher than
69% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. NAS:AMAG: -9.09 )
Ranked among companies with meaningful ROA % only.
NAS:AMAG' s ROA % Range Over the Past 10 Years
Min: -44.82  Med: -13.1 Max: 16.42
Current: -9.09
-44.82
16.42
ROC (Joel Greenblatt) % -1164.47
NAS:AMAG's ROC (Joel Greenblatt) % is ranked lower than
63% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. NAS:AMAG: -1164.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AMAG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1164.47  Med: -510.9 Max: 475.79
Current: -1164.47
-1164.47
475.79
3-Year Revenue Growth Rate 60.80
NAS:AMAG's 3-Year Revenue Growth Rate is ranked higher than
89% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NAS:AMAG: 60.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AMAG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -78.7  Med: 10.3 Max: 278.5
Current: 60.8
-78.7
278.5
3-Year EPS without NRI Growth Rate -45.80
NAS:AMAG's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. NAS:AMAG: -45.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AMAG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.7  Med: -8.15 Max: 100
Current: -45.8
-51.7
100
GuruFocus has detected 3 Warning Signs with AMAG Pharmaceuticals Inc NAS:AMAG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AMAG's 30-Y Financials

Financials (Next Earnings Date: 2018-05-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

AMAG Guru Trades in Q1 2017

Paul Tudor Jones 22,300 sh (+99.11%)
Jim Simons 766,000 sh (+49.17%)
Joel Greenblatt 678,918 sh (+13.04%)
» More
Q2 2017

AMAG Guru Trades in Q2 2017

Joel Greenblatt 800,055 sh (+17.84%)
Jim Simons 778,800 sh (+1.67%)
Paul Tudor Jones Sold Out
» More
Q3 2017

AMAG Guru Trades in Q3 2017

Chuck Royce 575 sh (New)
Jim Simons 681,000 sh (-12.56%)
Joel Greenblatt 431,411 sh (-46.08%)
» More
Q4 2017

AMAG Guru Trades in Q4 2017

Pioneer Investments 67,100 sh (New)
Chuck Royce 859 sh (+49.39%)
Jim Simons 851,900 sh (+25.10%)
Joel Greenblatt 73,141 sh (-83.05%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-12-31 Reduce -83.05%0.1%$12.8 - $19.45 $ 18.9525%73,141
Joel Greenblatt 2017-09-30 Reduce -46.08%0.1%$16.55 - $20.45 $ 18.952%431,411
Joel Greenblatt 2017-06-30 Add 17.84%0.03%$16.1 - $24.65 $ 18.95-5%800,055
Joel Greenblatt 2017-03-31 Add 13.04%0.02%$21.4 - $35.85 $ 18.95-21%678,918
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CBAY, SZSE:002898, NAS:ADRO, NAS:DRNA, ASX:MSB, NAS:CRBP, NAS:CYTK, SZSE:300049, NAS:CARA, XKRX:087010, NAS:ARWR, XKRX:182400, NAS:IFRX, OSL:NANO, NAS:CORI, NAS:QTRX, TSE:7774, OSTO:CAMX, OSTO:KARO, SHSE:603538 » details
Traded in other countries:AMU.Germany,
Headquarter Location:USA
AMAG Pharmaceuticals Inc is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and to aid in the diagnosis of cancer.

Founded in 1981, AMAG Pharmaceuticals uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging.

Top Ranked Articles about AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Tuesday, February 27, 2018 at 8:00 a.m. ET
Recent Analysis Shows SBA Communications, AMAG Pharmaceuticals, Galectin Therapeutics, Xilinx, J.B. Hunt Transport Services, and Southern Market Influences — Renewed Outlook, Key Drivers of Growth
AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women
Antares Pharma Announces FDA Approval of Partner’s Product Utilizing Our QuickShot Auto Injector
AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)
AMAG Pharmaceuticals Awards $300,000 in Grants to Further Research in Preterm Birth and Neonatal Health
AMAG Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
AMAG Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
New Patent Issued to AMAG Pharmaceuticals Entitled "Methods of Reducing Risk of Preterm Birth"
Factors of Influence in 2018, Key Indicators and Opportunity within Xilinx, J.B. Hunt Transport Services, Southern, FirstEnergy, AMAG Pharmaceuticals, and Galectin Therapeutics — New Research Emphasizes Economic Growth

Ratios

vs
industry
vs
history
Forward PE Ratio 10.64
AMAG's Forward PE Ratio is ranked higher than
55% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 22.08 vs. AMAG: 10.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.85
AMAG's PB Ratio is ranked higher than
97% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AMAG: 0.85 )
Ranked among companies with meaningful PB Ratio only.
AMAG' s PB Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.25 Max: 6.99
Current: 0.85
0.57
6.99
PS Ratio 1.08
AMAG's PS Ratio is ranked higher than
97% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. AMAG: 1.08 )
Ranked among companies with meaningful PS Ratio only.
AMAG' s PS Ratio Range Over the Past 10 Years
Min: 0.75  Med: 5.78 Max: 505.93
Current: 1.08
0.75
505.93
Price-to-Free-Cash-Flow 7.74
AMAG's Price-to-Free-Cash-Flow is ranked higher than
91% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 30.41 vs. AMAG: 7.74 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMAG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.24  Med: 10.58 Max: 1492.35
Current: 7.74
3.24
1492.35
Price-to-Operating-Cash-Flow 4.44
AMAG's Price-to-Operating-Cash-Flow is ranked higher than
96% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 26.94 vs. AMAG: 4.44 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMAG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.03  Med: 10.35 Max: 1409.44
Current: 4.44
3.03
1409.44
EV-to-EBIT -3.71
AMAG's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. AMAG: -3.71 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -787.3  Med: -4.8 Max: 100.3
Current: -3.71
-787.3
100.3
EV-to-EBITDA -6.52
AMAG's EV-to-EBITDA is ranked lower than
99.99% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. AMAG: -6.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -148.3  Med: -5.2 Max: 479.9
Current: -6.52
-148.3
479.9
EV-to-Revenue 1.69
AMAG's EV-to-Revenue is ranked higher than
94% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. AMAG: 1.69 )
Ranked among companies with meaningful EV-to-Revenue only.
AMAG' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.3  Med: 3.5 Max: 435.3
Current: 1.69
0.3
435.3
Current Ratio 1.59
AMAG's Current Ratio is ranked lower than
79% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AMAG: 1.59 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 9.43 Max: 62.43
Current: 1.59
1.51
62.43
Quick Ratio 1.48
AMAG's Quick Ratio is ranked lower than
77% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. AMAG: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 9.2 Max: 61
Current: 1.48
1.4
61
Days Inventory 95.72
AMAG's Days Inventory is ranked higher than
63% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. AMAG: 95.72 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s Days Inventory Range Over the Past 10 Years
Min: 95.72  Med: 441.37 Max: 1713.48
Current: 95.72
95.72
1713.48
Days Sales Outstanding 59.16
AMAG's Days Sales Outstanding is ranked higher than
54% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. AMAG: 59.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.4  Med: 49.36 Max: 581.14
Current: 59.16
27.4
581.14
Days Payable 21.86
AMAG's Days Payable is ranked lower than
77% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 59.19 vs. AMAG: 21.86 )
Ranked among companies with meaningful Days Payable only.
AMAG' s Days Payable Range Over the Past 10 Years
Min: 11.5  Med: 130.3 Max: 2881.25
Current: 21.86
11.5
2881.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.40
AMAG's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. AMAG: -16.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMAG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.7  Med: -6.3 Max: 0.7
Current: -16.4
-28.7
0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.45
AMAG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.39 vs. AMAG: 0.45 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMAG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.39  Med: 5.53 Max: 96.83
Current: 0.45
0.39
96.83
Price-to-Median-PS-Value 0.19
AMAG's Price-to-Median-PS-Value is ranked higher than
96% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. AMAG: 0.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMAG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.71 Max: 237.57
Current: 0.19
0.18
237.57
Earnings Yield (Greenblatt) % -26.97
AMAG's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. AMAG: -26.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMAG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -458.4  Med: -8.7 Max: 6.6
Current: -26.97
-458.4
6.6

More Statistics

Revenue (TTM) (Mil) $603.20
EPS (TTM) $ -6.07
Beta0.92
Short Percentage of Float32.70%
52-Week Range $11.93 - 25.20
Shares Outstanding (Mil)35.37

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 614 511 534 596
EBIT (Mil $)
EBITDA (Mil $) 191 121 134 184
EPS ($) 4.20 0.63 1.49 2.45
EPS without NRI ($) 4.20 0.63 1.49 2.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}